Influenza

Influenza vaccination is especially crucial among children and adolescents with chronic medical conditions that put them at high risk for severe outcomes.

Ravi Jhaveri, MD, shares approaches to addressing common concerns among parents and guardians regarding the flu vaccine for children.

Ravi Jhaveri, MD, discusses challenges in patient access to flu vaccines, and comments on the need to increase opportunities for vaccination for all pediatric patients.

Ravi Jhaveri, MD, reviews the different types of influenza vaccines for pediatric populations, highlighting the differences between egg-based and cell-based flu vaccines.

Ravi Jhaveri, MD, comments on the burden of influenza on children, specifically secondary infections and post-flu fatigue.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A usability study demonstrated that individuals older than 18 years could self-administer the intranasal treatment or administer it to eligible patients aged 2 to 49 years, when given instructions and no additional guidance.

The combination vaccine candidates demonstrated a safety profile consistent with Pfizer’s COVID-19 vaccine. A phase 3 trial is anticipated to commence in the coming months, according to a press release from Pfizer.

A new study suggests that new information on who is most likely to have a reaction may help boost immunizations.

At IDWeek 2023, several authors share a study on mother-infant pairs, evaluating for differences in rates of influenza infections in infants.

Compared to clinician nudges alone, higher receipt of influenza vaccination among children with special risk medical conditions (SRMCs) was observed when their respective parents received an additional short message service (SMS) reminder.

As we head into cold and flu season, researchers try to answer the question of what physical interventions are best for infection prevention.

A new study notes that coinfections, amongst other issues, can complicate diagnosis and management of respiratory infections in children.

Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2024 flu season are quadrivalent.

Besides its influenza pipeline, mRNA technology is helping this pharmaceutical company create a number of new vaccines for cancer, rare diseases, and infectious diseases.

Previously available under an Emergency Use Authorization, the combination test can detect and distinguish COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The clearance comes ahead of respiratory season, which, according to BD, could result in another “tripledemic” threat.

From vaccinations to classroom behavior to math and reading levels, a discussion on how to best prepare children for the coming academic year.

Influenza vaccination is especially crucial among children and adolescents with chronic medical conditions that put them at high risk for severe outcomes.

In a report from the Centers for Disease Control and Prevention, it was shown that symptoms and hospitalizations associated with influenza this season are higher among children than adults.

Stay on the nice list with these tips to help stop the spread of winter respiratory viruses.

New surveillance data from the 2021-22 influenza show the impact of coinfection among younger patients.

In a recent study, infants born from mothers vaccinated against influenza were less likely to be hospitalized from the disease than those born to unvaccinated mothers.

Tell your patients to get their annual flu vaccines for best protection against illness.

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discussed the potential threat of a “triple epidemic” of RSV, influenza, and COVID-19, and how pediatricians can identify these viruses in their communities.

In 2022, Chile saw an influenza season with atypical timing and severity, indicating similar cases may occur in regions such as the United States.

Deborah Molrine, MD, Clinical Program Director, QIVc at CSL Seqirus, discusses CSL Seqirus’ cell-based quadrivalent seasonal influenza vaccine, along with the effectiveness of cell-based vaccines in children.

Gregg Sylvester, MD, MPH, chief health officer at CSL Seqirus, discusses an FDA-approved cell-based flu vaccine for children as young as 6 months, trends in childhood vaccination rates, and how to prepare for the upcoming flu season.

Ian McGovern, Epidemiologist, Senior Manager at CSL Seqirus, discusses new data on influenza gathered in a recent study, and how influenza rates are expecting to rise in the 2022 to 2023 flu season.

In a recent report, the American Academy of Pediatrics discussed how influenza affects children and how it can be prevented.

Hospitalized children treated with early oseltamivir (Tamiflu, Gilead Sciences) for influenza had a shorter stay and were less likely to be transferred to an intensive care unit or require other treatment.